Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …

Simple Summary There is currently a lack of useful tests to detect microscopic residual
disease in patients who have undergone surgery to remove their bowel cancer. This inability …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in
patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) …

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

Importance Adjuvant chemotherapy in patients with stage III colon cancer prevents
recurrence by eradicating minimal residual disease. However, which patients remain at high …

9 Background: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) has
the potential to select patients who may benefit more from standard-of-care (SOC) adjuvant …

Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may
identify patients at the highest risk of recurrence and help inform adjuvant treatment …

Studies in multiple solid tumor types have demonstrated the prognostic significance of
ctDNA analysis after curative intent surgery. A combined analysis of data across completed …

Background Accurate detection of patients with minimal residual disease (MRD) after
surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve …